Cholesterol‐lowering Agents and their Use
Christopher J Packard, Glasgow Royal Infirmary, Glasgow, UK
Allan Gaw, Glasgow Royal Infirmary, Glasgow, UK
James Shepherd, Glasgow Royal Infirmary, Glasgow, UK
Published online: May 2003
DOI: 10.1038/npg.els.0002265
Abstract
Increased cholesterol concentration in the bloodstream is an important risk factor in coronary heart disease. Clinical trials
have demonstrated the benefit of lipid‐lowering medication in preventing morbidity and death from coronary heart disease.
Keywords: dyslipidaemia; statin; fibrate; prevention; coronary
References
Barter PJ and
Rye KA
(2001)
Cholesterol ester transfer protein, high density lipoprotein and arterial disease.
Current Opinion in Lipidology
12: 377–382.
Brown MS and
Goldstein JL
(1997)
The SREB pathway: regulation of cholesterol metabolism by proteolysis of a membrane‐bound transcription factor.
Cell
89: 331–340.
Expert Panel
(2001)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
Journal of the American Medical Association
285: 2486–2498.
Gervois P,
Torra IP,
Fruchart JC and
Staels B
(2000)
Regulation of lipid and lipoprotein metabolism by PPAR activators.
Clinical Chemistry and Laboratory Medicine
38: 3–11.
Grundy SM
(1998)
Statin trials and goals of cholesterol lowering therapy.
Circulation
97: 1436–1439.
Illingworth DR
(2000)
Management of hypercholesterolemia.
Medical Clinics of North America
84: 23–42.
Martin MJ,
Hulley SB,
Browner WS,
Kuller LH and
Wentworth D
(1986)
Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men.
Lancet
ii: 933–936.
Rosenson RS and
Tangney CC
(1998)
Antiatherothrombotic properties of statins.
Journal of the American Medical Association
279: 1642–1650.
Ross R
(1999)
Atherosclerosis: an inflammatory disease.
New England Journal of Medicine
340: 115–126.
Stein EA,
Lane M and
Laskargweski P
(1998)
Comparison of statins in hypertriglyceridemia.
American Journal of Cardiology
81: 66–69B.
Wood D,
DeBacker G,
Faergeman O et al.
(1998)
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.
Atherosclerosis
140: 199–270.
Further Reading
Davies MJ
(1996)
Stability and instability: two faces of coronary atherosclerosis.
Circulation
94: 2013–2020.
Fruchart JC,
Staels B and
Duriez P
(2001)
PPARS, metabolic disease and atherosclerosis.
Pharmacological Research
44: 345–352.
Goldstein JL and
Brown MS
(2001)
Molecular medicine. The cholesterol quantet.
Science
292: 1310–1312.
Packard CJ and
Shepherd J
(1997)
Lipoprotein heterogeneity and apolipoprotein B metabolism.
Arteriosclerosis, Thrombosis and Vascular Biology
17: 3542–3556.
Pearson TA
(2000)
Population benefits of cholesterol reduction: epidemiology, economics and ethics.
American Journal of Cardiology
85: 20–23E.
Rubins HB,
Robins SJ,
Collins D et al. for the Veterans Affairs High‐Density Lipoprotein Cholesterol Intervention Trial Study Group
(1999)
Gemofibrozil for the secondary prevention of coronary heart disease in men with low levels of high‐density lipoprotein cholesterol.
New England Journal of Medicine
341: 410–418.
Scandinavian Simvastatin Survival Study Group
(1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
Lancet
344: 1383–1389.
Shepherd J,
Cobbe SM,
Isles CG et al.
(1995)
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
New England Journal of Medicine
333: 1301–1307.
Thompson GR and
Naumova RP
(2000)
Novel lipid regulating drugs.
Expert Opinion in Investigational Drugs
9: 2619–2628.